Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-006 first-line metastatic nonsquamous NSCLC study
2018-003824-35Phase 3Unknown
- Sponsor
- Merck & Co.
- Start
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of pembrolizumab, lenvatinib and pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: Number of participants with a dose-limiting toxicity. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-003824-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003824-35.